CVS says the new hospital, which will be based at Central Park, Avonmouth, will be custom-built with uniquely designed facilities, state-of-the-art diagnostic tools such as MRI and CT scanners, and a cutting-edge stereotactic linear accelerator for radiotherapy in cancer treatment, the only one of its kind for pets in England.
The hospital, which will open next summer, will employ over 100 people led by a team of Specialist veterinary surgeons and supported by residents, interns and registered veterinary nurses.
Planning permission has been granted for the project, and CVS is now appointing building contractors.
Richard Fairman, CEO of CVS Group, said: "We are extremely excited to be developing this innovative new specialist veterinary hospital in Bristol, providing the best animal care to pet owners across the South West. With state-of-the-art equipment and some of the highest qualified veterinary professionals, we are confident that the site will act as a centre of excellence in the veterinary world, and be a leader in Europe for cancer treatments.
"The new hospital signals our commitment to investing in cutting-edge technology to bring cancer treatment in pets to the next level. It will provide a number of employment opportunities and secure specialist veterinary skills in the Bristol area. We look forward to finalising development plans and opening the doors to pet owners in 2022."
The strange phenomenon was spotted by Veterinary Vision's clinical director Chris Dixon when he examined Dachshund called Margo, which had been referred for the treatment of a corneal ulcer and fungal infection.
Chris said: “I was assessing Margo’s eye and was very surprised to see a face smiling back at me.
"It perhaps doesn't bear quite the same resemblance as the Turin Shroud. Still, I've never seen anything like it before.
"The good news is that it does not appear to have affected her vision at all.”
Apparently the smiling face is still there, even after Chris performed a corneal graft.
Chris added: "I think we can safely say that Margo is a very happy dog, both inside and out!"
Virbac has launched a new 12 month version of Suprelorin, the reversible medical castration implant for dogs, widening the options for clients seeking an alternative to surgical castration.
Product manager Chris Geddes MRCVS said: "The launch of Suprelorin 12 gives practices the chance to offer dog owners a more convenient castration option. The implant renewal can now be included with their dog's annual boosters or health check.
"The slow-release implant is inserted at the back of the neck in the same manner as a microchip. There is no anaesthetic, no surgery and no scarring. The current implant, which contains 4.7mg active and lasts for around 6 months after insertion, will continue to be available for those wanting a more brief solution or as a trial.
"Deslorelin is a GnRH superagonist which causes suppression of LH/FSH, and therefore testosterone production, leading to temporary infertility."
For further information on Suprelorin/12, please call and ask to speak to one of our veterinary advisors on 01359 243243, or contact your local Virbac territory manager.
During the webinar, which took place earlier this month, senior officers and staff from the College explained the new guidance, what it will mean for the profession, and answered questions submitted by delegates.
The webinar was chaired by RCVS President Dr Melissa Donald MRCVS with a panel comprising Standards Committee Chair Linda Belton MRCVS, RCVS Registrar Eleanor Ferguson, and RCVS Head of Standards Gemma Kingswell.
The webinar included an overview of the main changes, the considerations to take into account when prescribing POM-Vs remotely, the circumstances under which POM-Vs cannot be prescribed remotely, the prescription of antibiotics, antifungals, antiparasitics and antivirals, and how the guidance will be enforced.
Eleanor Ferguson, RCVS Registrar, said: “We have also now published a range of practice-based scenarios to help explain how the new guidance should be followed in various circumstances, and in relation to different species.
"These scenarios cover a variety of different situations, including how the guidance applies to two or more practices with mutual clients, consultancy services and the prescription of long-term controlled drugs.”
A second webinar will be held on Monday 17th July, with priority for those who wanted to attend the June webinar but were not able to do because it was over-subscribed.
www.rcvs.org.uk/undercare
Bayer Animal Health has launched Remend Wound Spray Gel for cats, dogs and horses.
The new gel contains Remend's structurally modified hyaluronic acid (HA). Bayer says it provides a matrix for cellular events that occur during the proliferative phase of the healing process, which has been shown to enhance healing1, and can promote rapid wound closure
Georgie Hollis BSc from www.vetwoundlibrary.com said: "Managing wounds can be challenging in veterinary practice; the progression of wound healing can be influenced by many factors, and selecting an appropriate product to apply should be based on the needs of the individual wound. A product that provides a moist healing environment and support of the proliferative phase ensures that cellular activity is optimised, helping to improve healing times and minimise scar tissue."
Bayer says Remend Wound Spray Gel is designed for use as part of the overall management of wounds; additional measures such as lavage, debridement and control of infection are equally important, as is giving consideration to any secondary factors that may delay healing if not addressed. The product aims to achieve greater compliance amongst owners by providing an effective management option that is easy to apply. A single application may be sufficient to enhance wound closure in fresh uncomplicated wounds; however more complex wounds may require multiple applications in order to accelerate closure.
For more information, visit: www.vetcentre.bayer.co.uk
References
Available for download now, the MobiVet Veterinary Formulary App is designed to make drug calculations and prescribing faster, easier and safer. It contains dose rate and interval data for over 250 drugs commonly used in small animal practice.
Searchable by drug name or trade names, with species-specific dosing information, the app calculates doses based on the patient type, weight, or body surface area as appropriate. MobiVet also provides a checklist of known relevant drug interactions for each medication, to prevent prescribing errors.
Stuart says an iOS version is in production.
To download the Android version, visit: https://play.google.com/store/apps/details?id=com.project.user.drug_formulary&hl=en
The survey, which takes about 5 minutes (I timed it), is designed to canvas opinion about the priorities for learning and development.
Rich Casey, Junior Vice President of the VMG (pictured right), said: "From marketing to HR to financial planning and all points in between, today’s veterinary leaders require expertise in every aspect of running a successful business.
"We want to create a truly valuable, constructive and evidence-based CPD calendar for next year. Views from those working in the profession will help us to fully understand what good leadership and management look like in the veterinary world and we will then make sure that the programme promotes best practice in these important areas. We thank everyone who takes the time to complete the survey."
The survey can be accessed here: https://www.surveymonkey.co.uk/r/VETCPDPR
The study was part of a research project called VetCompass, through which the RVC, in collaboration with Vets Now, collects anonymised clinical information on over 6 million companion animals under veterinary care in the UK.
The study investigated bitches presented with difficulty giving birth (dystocia) from among almost 20,000 bitches attending 50 Vets Now surgeries. Researchers found that out of 20,000 bitches receiving emergency veterinary care, 3.7 per cent of these were treated because of difficulties encountered giving birth.
The most commonly affected breeds were the French Bulldog (15.9 times more likely), Boston Terrier (12.9 times more likely), Chihuahua (10.4 times more likely) and Pug (11.3 times more likely).
Dr Dan O’Neill, a companion animal epidemiologist within the VetCompass Programme, said: "Giving birth in dogs is not always a benign process and our research shows this risk is especially exacerbated in some common brachycephalic and toy breeds. Prospective owners should bear these welfare costs for high risk breeds in mind when choosing their new puppy."
Caroline Kisko, Kennel Club Secretary, said: 'VetCompass' research will not only enable dog breeders to make responsible breeding choices to improve the health of these dogs, it will help to highlight what puppy buyers need to be looking out for if they are intent on owning one of these breeds. If people are choosing a breed simply for its looks and are not going to a reputable breeder, they are likely to face high vet costs and a lifetime of heartache."
This study builds on previous 'purchasing' research by the RVC which found that appearance is the number one reason why owners purchase flat-faced breeds, even though their large, round, wide-set eyes, and flat rounded faces are linked with a variety of inherited diseases.
Dr Rowena Packer, lead author of the study and Research Fellow at RVC, said: "Potential puppy buyers attracted to the appearance of these breeds should seriously consider whether they are emotionally and financially prepared to take on a breed with high risks of health complications, and consider whether alternative, lower-risk breeds would better fit their lifestyle."
The new aids will make their debut at this month's Vet Festival (20-21 May 2022, Loseley Park, Surrey).
The Flexi-Wedge (pictured) positioning aid aims to deliver both better quality and easier to interpret imaging, and to facilitate the ideal positioning of surgical patients.
The second product is the Saddle-Sandbags, which The Big Dog Bed Company says address two problems – the need to hold a patient in place without loading weight to any part of the body and the tendency of existing sandbags to leak sand after a few months of manipulation to different shapes.
Dru Ross, Director at Big Dog Bed Company said: “Support wedges are obviously widely used in the veterinary field.
"The difference with the design of the Flexi-Wedge is that they can be held securely in the desired position and are fully adjustable, making them suitable for a wide range of patient size and shape”.
“The Saddle-Sandbag is designed for those situations when a limb needs to be held out securely without any load on it and standard sandbags are not suited to this purpose.
"There is no need to manipulate the sandbag to the desired shape.
"The weight is split between two bags joined by a broad central strap so the strap is placed round or over the limb”.
James Weston, Managing Director at Northwest Referrals was one of the first to use the Flexi-Wedge.
James said: “I’ve never had such a straight spine when scanning a greyhound before using these supports. Every CT scanner should be sold with these”.
Patrick Harte MRCVS from the The Sidings Veterinary Surgery said: “The weighted ends make these sandbags much easier to handle.
"The larger aid is excellent for holding upper thoracic limb out of the way for lateral views of the elbow, for instance and the width of the flat part of the aid is perfect for wrapping around the antebrachium of the thoracic limb.”
The Flexi-Wedges and the Saddle-Sandbag products use waterproof, antibacterial, wipe clean fabrics in which the seams are thermally welded so no moisture can enter and no sand can escape.
The Flexi-Wedges are available in two lengths 60cm and 90 cm.
They are supplied with wipe clean straps that can be tailored to the size of table on which they are used.
The Saddle-Sandbags are available in three sizes.
In one case, Tigga, a 17-year-old cat with an itchy and destructive tumour on her nose, was in complete remission within 44 days. In another case, a tumour vanished in a dog where the aim of the treatment was only to shrink the mass before an operation to remove it.
NDSR, which is based in Bletchingley, is the only referral centre in the UK and one of very few in the world offering electrochemotherapy in pets.
Electrochemotherapy is given in two stages.
First, the patient is given a mild dose of intravenous chemotherapy in the normal way and then, using a probe, a precise electrical charge is given to the area on or around the tumour.
This temporarily opens up tiny holes in the cells, big enough to allow the drug to enter, which then close again in microseconds. This means the drug will only attack cancerous cells, unlike normal chemotherapy, which also kills healthy cells.
Gerry Polton, clinical director of oncology at NDSR, said: "Normal chemotherapy works on the principle of being more damaging to cancer than non-cancerous tissue. Some cancers are more resilient, so there are differences in how they respond to treatment, and this can cause more harm to the patient.
"Electrochemotherapy involves clever anatomical targeting of a specific site and is an effective way of protecting healthy cells.
"The results we are seeing in cases like Tigga’s are unprecedented and we are learning about the procedure all the time. We are always looking for better ways of treating cancer without the effect of harming the patient indiscriminately and this has proved to be a very effective way of doing this."
According to NDSR, the results could help inform the development of the targeted treatment in humans, where electrochemotherapy is used in a small number of cases in the NHS.
At present, many clinical trials are carried out on laboratory animals which are bred with no immune system – but dogs have similarities in genetics to humans and have working immune systems, meaning they can provide a more accurate parallel for how the treatment may work in people.
Gerry said: "A pet dog would be a good model for human cancer studies. It's a mammal with a heartbeat, blood supply and working immune system.
"Progress with electrochemotherapy in animals is being made in parallel with progress in electrochemotherapy in the human field, and what we are learning may even inform what is happening in people.
"Electrochemotherapy is a form of treatment which Cancer Research UK describe as 'fairly new' on its website, with limited information about its effectiveness. So maybe something would be gained from learning together."
Working in collaboration with researchers at University of Texas, Southwestern (UTSW) Medical Center, the team has succeeded in using gene editing techniques on dogs to restore the expression of the dystrophin protein that is absent in DMD patients’ muscles to levels that could be life changing.
DMD is the most common, fatal, genetic disease that affects children. The same disorder also occurs in many dog breeds. It is caused by mutations in the gene that encodes dystrophin, a crucial protein that helps protect muscle fibres and the heart when they contract. Patients with the disease produce effectively no dystrophin protein, so their muscles and heart become damaged during contraction, leading to inability to walk, skeletal deformities, breathing problems and heart failure. Patients with DMD have a life expectancy that does not go far beyond their twenties.
Researchers say that this preliminary research, published in Science, demonstrates an approach that could lead to an effective, in principle one-time treatment for DMD for the most common genetic mutations affecting human patients. Through a single intravenous injection, researchers have been able to modify the dystrophin gene in many muscles of the body, including the heart, with the result that some muscles now had almost the normal amounts of dystrophin protein.
The team, led by Eric Olson, Ph.D., professor and chair of the Department of Molecular Biology at UTSW Medical Center and founder and chief science advisor of Exonics Therapeutics, and Richard Piercy, Ph.D., MRCVS, Professor of Comparative Neuromuscular Disease at the RVC, identified a naturally-occurring mutation in the dystrophin gene in a dog brought to the RVC’s Small Animal Referral Hospital.
Working now with relatives of this first dog, the combined group has used a technique called ‘SingleCut CRISPR gene editing’, where the researchers target a specific region of the subject’s own DNA. Harmless viruses encoding the gene-editing protein CRISPR/Cas9 were used to express the enzyme in muscle to cut the dogs’ own DNA at a precise location in the dystrophin gene through use of a molecular guide. The body’s own processes then repair the cut, which results in removing the negative effects of the existing mutation.
The researchers have demonstrated that dogs treated in this way had restored ability to produce large amounts of the dystrophin protein in their muscles and heart, and in the dog with the highest dose, cardiac muscles were found to have restored dystrophin protein to up to 92% of normal amounts after the single treatment.
The team believes this is the first time that this form of gene editing therapy has been conducted after birth in an animal larger than a rodent. With further longer-term research, efficacy and safety testing, it is hoped that this breakthrough will have human application. This treatment may be a significant step toward developing a gene editing therapy to repair genetic mutations for DMD, as well as a range of diseases caused by genetic mutations.
Richard Piercy, Professor of Comparative Neuromuscular Disease at the RVC, said: "Researchers have been looking for an effective and durable treatment for Duchenne muscular dystrophy for many years. This SingleCut gene editing approach, pioneered by Dr. Eric Olson’s group, has the potential to be a one-time treatment that could restore dystrophin protein. It is hugely exciting that through a single intravenous injection we’ve been able successfully to modify the dogs’ own DNA so they start generating dystrophin protein again. There is more work to be done, but with this exciting breakthrough, we feel we are a significant step closer to finding an effective treatment.
"A great many genetic diseases affect humans, dogs and other species - many, like DMD - with tragic consequences and this form of gene editing treatment might well be applicable in many of them. We’re hopeful that we’re paving the way for future research into treating some of the most serious genetic conditions that affect us today."
Kriptazen is supplied with a twist-adjustable and weight-graduated dosing pump which means farmers can administer a precise dose up to 60kg without having to calculate it in ml’s first. Virbac says this will help to reduce the risk of incorrect dosing and toxicity issues.
Virbac’s Technical Product Manager Rosie Naylor said: "We are delighted to bring Kriptazen to the market. The trusted active halofuginone, along with the innovative weight graduated dosing pump, provides practices with added peace of mind when it comes to treatment."
For more information, contact your Virbac Territory Manager.
Bayer Animal Health (makers of Advocate, Advantix, Advantage, Seresto, Profender, Drontal and Droncit) has launched 'It's a Jungle Out There', an educational initiative aimed at simplifying parasite control for veterinary practices and pet owners alike.
The impressive-looking initiative comes on the back of research carried out by the company which found:
Dan White, Group Product Manager for Bayer's Animal Health division said: "Our research concluded that many vet practices are missing an opportunity because of a lack of clarity regarding best practice for parasite control. With ongoing support and practical development tools, Bayer's 'It's a Jungle Out There' Programme is an educational initiative which will arm vet practices with the tools they need to make parasite control clearer and more accessible to owners, helping to ensure the UK is a nation of healthy parasite-free pets and happy owners."
Bayer says the first stage of the 'It's a Jungle Out There' initiative aims to help the veterinary community identify opportunities where they can help to improve pet owner compliance. Vet practices will then be supported in developing a parasite protocol which will then be launched to consumers via a heavyweight advertising and PR campaign.
The initiative comprises a new educational website: www.jungleforvets.co.uk, which includes practice development workbooks, market research and trends, extensive technical information on a wide variety of parasites and CPD assessments. Additional downloadable content includes a range of materials such as images, videos, downloads and web buttons.
From the end of August, practice support materials will be available including a waiting room display pack, parasite guide and dispenser, vet nurse reference guide, waiting room posters, lifestyle questionnaire, badges and static window stickers.
The pet owner focus will begin in September and will include an interactive website, advertising and an extensive print and broadcast PR campaign with celebrity ambassadors David Bellamy and TV vet Steve Leonard. This activity is aimed at driving owners towards their vet practice for advice on parasite risks.
The survey found that 51% of cat and dog owners didn't research their pets breed before buying. Of the 22% who then regretted their decision, 31% said it was because they didn’t have enough time to look after the animal, 18% because they turned out to be allergic to the animal, and 16% because they didn’t like their pet’s personality.
Apparently dog owners were more likely to regret their new pet (26%) than cat owners (16%).
Sainsbury’s has therefore launched the Pawfect Match tool, designed to help future pet owners to make informed decisions when choosing the most suitable breed for them. The pet picker asks you a number of questions about your circumstances and makes a number of suggestions based on how you answer.
Sainsbury's campaign is being fronted by Scott Miller MRCVS, who said: "I am saddened to hear that so many pet owners are regretting the animals they have chosen as companions. Dogs and cats come in all shapes and sizes, and have different temperaments. Looking after a pet is a huge commitment so it is important that people undertake adequate research before buying a pet to ensure it is a happy experience."
COMMENT
I tried Sainsbury's pet picker and it recommended a Basset Hound as the first choice. Fair enough. I always think they look like the living embodiment of the word 'hangdog', which is not really my cup of tea. Luckily, the tool makes more than one suggestion. One of the criteria I'd specified was 'quiet and calm', so the second recommendation, a whippet, was fine. But the third caught my eye. A Border Collie. What? Whaaaaaat? Quiet and calm? A Border Collie. Are you having a laugh? I thought Border Collies usually need to be sent to some sort of asylum.
Still, if Sainsbury's tool encourages more people to think harder about their choice, that's no bad thing. But they might like to rethink the Border Collie recommendation.
I invited Marc Abraham to come and answer some of the concerns raised on VetSurgeon about the ITV Pets Undercover programme.
His PR agency has instead pointed me in the direction of a response he has posted on his own website this morning. Click the link below.
http://www.marcthevet.com/response-to-%e2%80%98pets-undercover%e2%80%99/
The original editorial team of Daniel Brockman and David Holt has been joined by Gert ter Haar to produce a new edition which considers the substantial progress that has been made in this important field, including the challenges of treating airway abnormalities linked to brachycephalism, the constraints of complex bony anatomy and rich vascularity of the head when performing radical surgery, and the treatment of trauma.
The book includes a number of new techniques, including dorsal rhinotomy and total ear canal ablation.
The BSAVA says operative techniques, instructive photographs and full-colour illustrations remain a key feature of the manual, which is aimed at the general veterinary practitioner.
The BSAVA Manual of Canine and Feline Head, Neck and Thoracic Surgery, 2nd edition is available from the BSAVA website: www.bsava.com or by phone: 01452 726700.
Ceva says this is the first time it has advertised Feliway Friends - designed to help cats live together in harmony - on television. It will be rotating the Feliway advert with one explaining the benefits of the Adaptil Calm On-the-Go Collar.
Both advertisements are 30 seconds long and the campaign runs until the end of June. It will target 24.5 million pet owners and will air on all Channel 4 and Channel 4 partner channels, including Channel 4, E4, More4, Film4, Drama, Good Food, Really, W and Home.
Abigail King, product manager for Feliway and Adaptil at Ceva, said: "Our summer TV advertising campaign will raise awareness of how Feliway Friends and Adaptil Calm On-the-Go Collar can help pets with behavioural issues and drive customers to veterinary practices for further information and to purchase product."
For further information, visit www.feliway.com or www.adaptil.com.
Virbac has launched Milpro, a palatable milbemycin / praziquantel-based broad-spectrum wormer for dogs and cats.
Milpro is offered in tablet sizes suitable for dogs, small dogs or puppies, cats and small cats or kittens for ease of dosing. It is presented in 4, 24 and 48 packs.
As an aid to owner education and compliance, packs of Milpro use 'Blippar Augmented Reality'. Owners download the Blippar app and scan the front of a pack of Milpro or a dispensing envelope, whereupon the pack becomes animated and various interactive options appear, including educational videos, a built in reminder system and other product information.
Simon Boulton MRCVS, Marketing Manager for Companion Animals at Virbac, said: "The practice team has a crucial role to play in reminding owners that regular worming is essential for their pet's health. With the introduction of Milpro, we are extending our parasiticide range and offering practices an alternative solution.
"With compliance such an issue, we want to use 21st century communication to help practices to get the message across. The result is the introduction of an interactive element to our packs with the use of the Blippar platform. It enables us to create 'Augmented Reality' experiences through which we can provide comprehensive information to owners in an eye-catching and easily accessible way with the aim of boosting compliance and, ultimately, welfare.
"We believe the combination of the small tablet sizes and the innovative packaging will prove attractive and convenient to owners, making Milpro a successful product for practices".
Practices can also request an interactive waiting room poster which enables owners to watch a video on the poster on the importance of worming.
Currently Principal of the Royal Veterinary College, University of London, and previously Dean of the University of Glasgow’s School Of Veterinary Medicine, Stuart has been a member of RCVS Council since 2005, and served as RCVS President in 2014-15.
As chair of the Education Policy and Specialisation Committee in 2011, Stuart oversaw the College’s review of veterinary specialisation, which also led to the new Advanced Practitioner status.
He has also been a driving force behind the joint RCVS and BVA Vet Futures project since its inception in 2015.
As Chair of the RCVS Governance Panel, he recently saw through reform of the College’s governance arrangements to improve the efficiency and accountability of its decision-making processes.
Stuart has also chaired the RCVS Science Advisory Panel.
He continues to chair the College’s Mind Matters Initiative, which aims to improve the mental health and wellbeing of all those in the veterinary team.
A particularly notable achievement during his Presidential year was to allow UK veterinary surgeons to use the courtesy title ‘Doctor’ if they so wished.
Lizzie Lockett, RCVS Chief Executive said: "We have been incredibly fortunate to have someone of Stuart’s calibre, character and international renown on our Council for so many years. His contributions and commitment to the RCVS, as well as to the wider veterinary professions, are as significant as they are often understated.
"On behalf of RCVS Council and all the staff, I should like to say how delighted we are that he has been honoured in this way. Such recognition is very much deserved and we send him our warmest congratulations."
Ms Mulvey faced a number of charges relating to the treatment of a cat called Spooky: that she failed to provide Spooky’s owner, Mrs Parsons, with either Spooky’s lab results or an adequate explanation as to why they could not be provided; that she failed to respond adequately or at all to communications from Mrs Parsons; that she failed to respond to requests from the College for information relating to Continuing Professional Development (CPD), her professional indemnity insurance (PII), and her correspondence with Mrs Parsons.
At the beginning of the hearing Dr Mulvey admitted the facts to all the charges, and accepted that they constituted disgraceful conduct in a professional respect. The Committee had been provided with written evidence from Mrs Parsons, her husband, and four College staff, namely Gemma Crossley, Maria Fearon, Robert Girling and Michael Hepper.
Mrs Parsons provided a statement in which she spoke of how, in August 2016, she had taken Spooky to CornYard Veterinary Centre for a skin irritation where she was seen by Dr Mulvey.
Dr Mulvey decided to take blood tests and send them to the laboratory, but they agreed to defer them actually being tested until Mrs Parsons gave permission. Mrs Parsons then returned to the practice with Spooky to take said samples, after which followed a series of attempts to contact Dr Mulvey for the test results. Finally, in October, she demanded a refund, after which she began a small claim in County Court.
Mr Parsons went to the practice at the beginning of December 2016 and obtained the refund. At this point Mrs Parsons made a complaint to the College. The Committee received information from Mr Parsons, who corroborated the facts of the complaint, and from College staff who confirmed the many attempts to contact Dr Mulvey, starting with requests for documents by Ms Crossley and Ms Fearon, repeated requests for CPD and PII information from Mr Girling, and finally a hand-delivered letter by Mr Hepper, during which he learnt that her PII had lapsed at the beginning of 2017.
The College submitted that Dr Mulvey’s conduct fell far below the standard expected of a veterinary surgeon. It submitted that failing to provide the test results and communicate with the Parsons could have had a negative impact on animal welfare and damaged the reputation of the profession, while having PII is a fundamental obligation of the RCVS Code of Professional Conduct. Finally, not responding to the College about the concern raised, CPD or PII compromised the College’s ability to maintain public confidence in its regulatory processes.
The Committee considered that no harm had actually come to Spooky and that there were problems with the testing laboratory which slowed down the process. In addition, some of the lack of communication was due to a receptionist not following protocol, and Dr Mulvey was going through a particularly difficult part of her life and was clinically understaffed. The Committee heard from four different character witnesses, and were given 16 more written testimonials.
The Committee heard that in 2013 there had been complaints from three separate clients, all of which concerned Dr Mulvey’s failure to communicate and to process insurance claim forms, after which she agreed to participate in the Performance Protocol and entered into undertakings with the College.
The Committee having considered all the facts and background circumstances found that Dr Mulvey’s conduct was disgraceful in a professional respect.
The Committee went on to consider what sanction was appropriate. In reaching its decision the Committee took into account a number of aggravating factors, namely that there was a slight risk to the health of Spooky and that the disgraceful conduct occurred over a prolonged period of time. The Committee also considered that there was blatant disregard of the role of the RCVS and the systems regulating the profession.
In determining the sanction the Committee also considered mitigating factors, including that Dr Mulvey, apart from those previous concerns, had a long and unblemished career and that she’s made a huge difference to the health of the animals within her care. She also admitted her shortcomings, and had very impressive references.
The Committee therefore determined to postpone its decision on sanction for a period of one year on condition that Dr Mulvey enter into the following undertakings:
To agree to the appointment of a veterinary surgeon as a work place supervisor by the College and meet with them at least once every month
Allow the supervisor access to all aspects of running of the practice and to implement any recommendations made by the supervisor relating to the administration of the practice and the provision of out of hours’ cover.
To allow the supervisor to provide a report in relation to the matters set out in 2 above to the RCVS at least one month before the resumed hearing of this case.
To appoint within two months an experienced Practice Manager (who does not need to be full time).
To enrol in the voluntary Practices Standards Scheme and to achieve the Core standards of the Scheme within the next 12 months.
To submit a plan to the supervisor of CPD for the next twelve months within one month of agreeing to these undertakings. The plan should then be implemented and shall include aspects of practice management.
To pay all of the costs of complying with the undertakings, with the exception of the costs associated with the appointment and performance of the supervisor.
Ian Green, chairing the Disciplinary Committee and speaking on its behalf, said: "The Committee recognised that Dr Mulvey has been subject to undertakings before and yet committed the disgraceful conduct the subject of this inquiry. But it bore in mind the context of that conduct and it observes that the undertakings previously imposed in reality address a particular aspect of her practice.
"This Committee hopes that when the matter is relisted before it, the Respondent will be able to demonstrate that she has finally been able to address her administrative shortcomings. If she cannot do so, she will know that the Committee that sits on her case at the resumed hearing is likely to have more restricted options for disposal of her case."
The newsletter will include anaesthesia updates, bulletins and recaps, access to videos and downloadable resources.
Articles in Anaesthesia1ST are being written by Jurox’s technical advisors in collaboration with anaesthesia specialists such as Carl Bradbrook (European Veterinary Specialist in Anaesthesia and Analgesia and an RCVS Recognised Specialist in Veterinary Anaesthesia) and Ian Self (European Specialist in Veterinary Anaesthesia and Analgesia, Associate Professor in Veterinary Anaesthesia and Analgesia, Faculty of Medicine & Health Sciences, University of Nottingham).
The first newsletter launched on 15th May and included: ‘Capnography I – not just a load of hot air’, ‘Perspectives on premeds – Alpha-2 agonists’ and ‘What’s new in anaesthesia? Highlights of recent preoxygenation paper’.
Articles in future editions will include: ‘Capnography II – what happened to the elephants?’, ‘Pain, what a pain! Local and regional nerve blocks improve outcomes and welfare of patients’, “The Big Chill – temperature management in sedated and anaesthetised patients’ and ‘Perspectives on premeds – a complete series of articles covering the ins and outs of the different agents, how they compare and recommended use in the different patient types’.
Jurox says that downloadable resources will include a capnography cheat-sheet detailing different traces and their meaning, premedication drugs comparison tables and pre and post rabbit anaesthesia check-lists.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "We take great pride in our investment in educational initiatives to enable veterinary professionals to deliver best practice anaesthesia to their clients. The new Anaesthesia1ST newsletter further demonstrates our commitment to educational support resources to enable veterinary professionals to attain and maintain 1ST class anaesthesia for all patients."
To sign up to the Anaesthesia1ST newsletter, click here, visit the Alfaxan website – www.alfaxan.co.uk, contact your local Jurox technical sales representative or email Jurox at: info@jurox.co.uk.
The Disciplinary Committee heard three charges against Dr Jones.
The first and second charges were that, in March 2018, Dr Jones made signed entries in the passports and made corresponding entries in clinical records of four horses indicating that he had administered an influenza vaccination booster to each horse on 15 March 2018 and in relation to another horse a tetanus booster, when in fact he had administered the vaccination boosters on 21 March 2018, and that his conduct was misleading, dishonest and undermined the integrity of a vaccination process designed to promote animal welfare.
The third charge was that, on or around 21 March 2018, Dr Jones failed to make any entries in the clinical records for a horse in relation to an examination on 21 March 2018.
At the outset of the hearing Dr Jones admitted the facts in the first and second charges, and accepted that his actions were misleading, dishonest and that they undermined the integrity of a vaccination process. However, he disputed certain aspects of the written statements of the College’s witnesses. In particular he wanted his conduct to be taken in the context of the pressures that he was working under on that day, primarily that he was in a stressed state having had to euthanase a valuable stallion at the conclusion of his previous client appointment.
Dr Jones did not admit the third charge, explaining that he did not remember examining the horse on 21 March 2018 as alleged.
Based on Dr Jones' own admissions, the Committee found the first and second charges proven.
Regarding the third charge, the Committee heard evidence from the horse’s owner who said they were present during the examination taking place and the Committee was satisfied that the respondent did examine the horse on 21 March 2018 and that he had a duty to make a brief clinical note on the examination. As Dr Jones admitted that he made no such note, the Committee found the charge to have been proven to the requisite standard.
Having found the charges proven, the Committee then went on to consider whether or not Dr Jones’ proven conduct amounted to serious professional misconduct. The Committee, having considered the aggravating and mitigating factors, found that Dr Jones’ conduct as found proved in relation to both charges one and two, did constitute serious professional misconduct.
However, with regards to charge three, the Committee accepted that the respondent simply forgot that he had examined the horse and, therefore, the Committee was not satisfied that the failure to compile a record entry covering the horse’s examination constituted serious professional misconduct.
The Committee then considered what sanction to impose on Dr Jones in relation to the facts found proven in charges one and two. In doing so it took into account the 78 written testimonials and 4 character witnesses called on behalf of Dr Jones.
Ian Green, who chaired the Committee and spoke on its behalf, said: "The Committee’s decision on sanction has been based on an acceptance that the respondent’s conduct on this occasion was out-of-character, as the evidence of his character witnesses and the contents of the letters submitted in his support by his clients and other veterinary colleagues assert. The Committee also accepts that the respondent self-reported himself to his employer and to the College and has made a full and frank admission of his wrongdoing.
"Consideration was given to whether the sanction of a reprimand and/or warning as to future conduct would adequately reflect the gravity of the misconduct, however, after careful reflection it was concluded that such a sanction could not be justified. The reason is that acts of falsification involve acts of dishonesty by a professional person acting in a professional capacity, and the gravity of the matter arises not simply from the dishonesty but also from the possible consequences of the false certification. It should be clearly understood by members of the veterinary profession that, in appropriate false certification cases, the sanction of removal from the Register is one which may well be imposed."
The Committee therefore decided that suspending Dr Jones from the Register for two months would be the most appropriate sanction.
The Kennel Club has announced that the Crufts Best of Breed (BOB) winners in two of the high profile breeds - the bulldog and the Pekingese - failed their veterinary checks, so the breeds were not represented in the utility and toy group judging.
The British Veterinary Association says it welcomed the Kennel Club's initiative to put the veterinary checks in place for the BOB winner in the 15 high profile breeds at all championship dog shows starting at Crufts this year.
The 15 breeds have been identified as having particular health problems often due to poor conformation as a result of having been bred with exaggerated characteristics. The veterinary checks ensure the BOB winners are not suffering as a result of their conformation, such as eye problems, skin disease, lameness or breathing difficulties, which should have been identified by the judge.
Carl Padgett, President of the BVA, said: "Breeding dogs with exaggerated features must be tackled robustly. The veterinary checks are sending out a strong message that dogs with health problems will not win in the show ring, and only visibly healthy dogs will be rewarded.
"Dog showing can be a force for good for dog breeding and education but the veterinary checks on the first two groups at Crufts have highlighted the health problems that all too often affect man's best friend.
"We hope this strong action by the Kennel Club will be a wake-up call to those breeders and judges that still need to embrace the message that health should always be at the top of the agenda."
Nine-year-old Nigel the puma, from Lincolnshire Wildlife Park, was suffering from a deteriorating arthritic condition, which was causing loss of function in his front leg.
His veterinary team consulted an orthopaedic specialist and trialled medical management including steroids and Solensia, but Nigel was unresponsive to treatment.
This led to a severe debilitating limp and pain, leaving a choice between amputation or euthanasia.
Nigel's treatment was funded by donations from visitors to Lincolnshire Wildlife Park, which is a registered charity that was originally established as a sanctuary for parrots in the early 1990s, who raised nearly £5,000 following a fundraising campaign.
The operation took place in a sterile theatre set up in Nigel’s enclosure, where the entire limb was removed, including the scapula.
After an intense five-hour operation, led by Iain Cope, veterinary surgeon and practice owner at Vets4Pets Newmarket, and Shannon Grimwood, veterinary nurse at Vets4Pets Newmarket, Nigel is now on the road to recovery and adapting well to life with three legs.
Iain said: “Nigel’s case was certainly unique and one we haven’t come across before. Working alongside Lincolnshire Wildlife Park and a team of local vets and veterinary nurses, we applied our knowledge of domestic cat amputations to a big one.
“The approach was extremely similar, and the operation ran as smoothly as possible.”